Frontiers in Clinical Drug Research - Anti Infectives: Volume 8 E-Book
69,91 €
Mehr erfahren.
- Herausgeber: Bentham Science Publishers
- Kategorie: Wissenschaft und neue Technologien
- Serie: Frontiers in Clinical Drug Research - Anti Infectives
- Sprache: Englisch
- Veröffentlichungsjahr: 2006
Frontiers in Clinical Drug Research – Anti infectives is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of infectious diseases. The scope of the book series covers a range of topics including the chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases. Reviews in this series also include research on multi drug resistance and pre-clinical / clinical findings on novel antibiotics, vaccines, antifungal agents and antitubercular agents. Frontiers in Clinical Drug Research – Anti infectives is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of anti infective drug discovery and epidemiology.
The eighth volume of this series presents comprehensive reviews of interest to readers interested in the treatment of inflammatory diseases, new antiviral agents and strategies, specific antiprotozoal drugs that work against leishmania and helminths, and a study on potential agents against American foulbrood in honey bees. The 7 reviews included in this volume are:
- Monoclonal antibodies as therapeutic agents for inflammatory diseases
- Pharmacotherapy of emerging antiviral agents
- Antiviral activity of vitamin D and COVID-19: current understanding
- Anti-infectives to combat leishmaniasis
- Anthelmintic drug discovery: current situation and future perspectives
- Therapeutic targets for emerging Zika virus infection and vaccines in clinical trials
- Agro-industrial waste: new source of raw material for the control of American foulbrood in honey bees
Sie lesen das E-Book in den Legimi-Apps auf:
Seitenzahl: 666
Ähnliche
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Usage Rules:
All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.Bentham Science Publishers Pte. Ltd. 80 Robinson Road #02-00 Singapore 068898 Singapore Email: [email protected]
PREFACE
The 8th volume of Frontiers in Clinical Drug Research – Anti Infectives comprises seven chapters that cover several important topics including the role of monoclonal antibodies, emerging antiviral agents, and the current situation on antiparasitic drug discovery.
In chapter 1, Capela et al. discuss the role of monoclonal antibodies as therapeutic agents for inflammatory diseases. Doshi et al. explore the pharmacotherapy of emerging antiviral agents in chapter 2 of the volume. Al-Azzawi and Sakr discuss how vitamin D can be used as a preventive or treatment agent for COVID-19. Das et al., in chapter 4, present an overview of anti-infectives to combat leishmaniasis. Rayes et al., in chapter 5, summarize the current situation on antiparasitic drug discovery and discuss the use of C. elegans at the initial steps of drug development. In the next chapter, Kannan et al. discuss the emergence of the Zika virus and its detailed genome structure and replication cycle. Fuselli et al., in the last chapter of the volume, give an insight on agro-industrial waste, a new source of raw material for the control of American foulbrood in honey bees.
I would like to thank all the authors for their excellent contributions that should be of great interest. I would also like to thank the editorial staff of Bentham Science Publishers, particularly Mr. Mahmood Alam (Editorial Director of Bentham Science Publishers), Mr. Obaid Sadiq (In-charge Books Department), and Miss Asma Ahmed (Senior Manager Publications) for their support.
List of Contributors
Monoclonal Antibodies as Therapeutic Agents for Inflammatory Diseases
Jéssica Bairos1,$,Emanuel V. Capela1,$,*,Ana P.M. Tavares1,Mara G. Freire1Abstract
Inflammation is a physiological process caused when an agent (chemical, biological or physical) transcends the primary defense barrier of an organism, setting a series of biological reactions to restore the integrity of such organism, thus playing a central role in the fight against those pathogens. Uncontrolled amplification of these events may lead to undesirable pathological manifestations such as cancer, diabetes, and cardiovascular, neurological, and chronic inflammatory diseases. Monoclonal antibodies (mAbs) were first described in 1975, and since then, they have proven to be relevant therapeutic agents in a myriad of diseases. The US Food and Drug Administration (FDA) has already approved more than 90 mAbs for the treatment of several diseases, from which approximately 26% were specifically approved for the treatment of inflammatory diseases, for instance, rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, and palmoplantar pustulosis. This chapter provides an overview of the inflammation process and main biochemical mechanisms, together with a vision on the current state of the art of the mAbs-based biopharmaceuticals market and their application as powerful therapeutic agents for inflammatory diseases.
INTRODUCTION
Inflammation consists of the natural protective response of the body to injury. It occurs when an agent (chemical, physical or biological) transcends the primary defense barrier of the organism [1, 2]. It plays a central role in the fight against pathogens and can set biochemical reactions to restore homeostasis through the
activation of specific components, which act through the destruction or isolation of the aggressor agent [3, 4]. Inflammation can be manifested as an acute process comprising three main events: i) increased blood flow, ii) development of edema, and iii) migration of leukocytes to the inflammatory focus [2]. Uncontrolled amplification of these events may lead to a chronic process, which is long-term and associated with the presence of lymphocytes fibrosis and tissue necrosis [5, 6]. This phenomenon causes undesirable pathological manifestations such as cancer, diabetes, and cardiovascular, neurological, and chronic inflammatory diseases [5, 6]. Therefore, this type of diseases’ progression fostered the search for effective alternative therapies, which is a crucial objective to be achieved in the coming years.
In recent decades, technological advances in bioprocess engineering have increased the interest in the development of alternative therapies for inflammation treatment, particularly recurring to biopharmaceuticals [7]. Biopharmaceuticals are biological macromolecules or cellular components that can be used in vaccines or as therapeutic agents. They are obtained by biological processes (in vitro or in vivo) and are extracted from biological sources, for example, tissues and organs, microorganisms, fluids of animals, mammalian cell cultures, insects, and also plants [7]. The main examples include recombinant proteins (e.g., monoclonal antibodies) and nucleic-acid-based products, which can be applied in the treatment of several inflammatory diseases, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and palmoplantar pustulosis [8]. Among them, monoclonal antibodies are the most used biopharmaceuticals, representing 53% of all biopharmaceuticals approved [9].
Monoclonal antibodies (mAbs) were firstly described by Köhler and Milstein in 1975 [10], and since then, they have become the new backbone of the pharmaceutical industry as they have exquisite target selectivity and specificity [10]. mAbs offer the most promising prospects for new therapeutic approaches for inflammatory diseases [11, 12]. The most successful applications of mAbs are in autoimmune and inflammatory conditions [13]. Furthermore, as a wide range of mAb-based agents targets several cytokines, chemokines, adhesion molecules, receptors, and various types of cells, it is expected that these therapeutic “magic bullets” [14] will greatly expand in the future while providing better personalized treatment for a wide range of diseases. In this chapter, the most important aspects and main biochemical mechanisms of the inflammation process are overviewed, followed by a current review on the mAbs-based biopharmaceuticals market and approved mAbs product/therapies for inflammatory diseases. The action mechanisms and features of some relevant mAbs are also discussed, highlighting the advantages of mAbs-based therapies, together with the steps required for their increased adoption and widespread use.
MONOCLONAL ANTIBODIES
Structure and Properties of Antibodies
Antibodies, usually referred to as immunoglobulins (Igs), are glycoproteins found in plasma and extracellular fluids [15]. They are essential biomolecules in the immune-humoral system of all vertebrates [15], being the line of defense of the immune system [16]. They are produced naturally by specific plasma cells, namely the B lymphocytes, in response to exposure to “foreign” molecules or other antigens [15, 16]. In their composition, they present one or more regions, the paratopes, which recognize and bind to the epitopes of the antigen. This molecular recognition allows the neutralization and/or elimination of the antigen, allowing the organism to protect itself against the action of microorganisms and other harmful species, such as foreign proteins [17-19], carbohydrates [19], peptides [17], bacteria [17, 19], viruses [17], fungus [18] or even cancer cells [18]. As a result, an effective immune response takes place, often involving the production of a vast array of antibodies that are structurally similar yet unique, thus enabling the multiple epitope binding onto a given antigen [17, 20].
Independently of their specificity, all antibodies are heterodimer proteins structurally composed with four polypeptides chains – two identical heavy chains (H) and two similar light chains (L), in a “Y”-like shape form (Fig. 1) [15]. Disulphide bonds and non-covalent bonds are held together with chains by the “hinge” region, which provides stability and flexibility to the antibody. Furthermore, all polypeptide chains contain variable regions (V), presenting considerable variations in their amino-acid composition and where the antigen binds [17]. The constant regions (C), located at the carboxyl-terminal region, are specific for effector functions [17]. The antibody chains are further divided into L and H sections – each L chain has a variable domain (VL) and a constant domain (CL), while each H chain has one variable domain (VH) and three constants domains (CH1, CH2, CH3) [15, 17, 21], as shown in Fig. (1).
The antibodies may undergo proteolytic digestion, giving rise to new antibody fragments – Fab (Fragment antigen binding) and Fc (Fragment crystalline) [15]. Some enzymes can be highlighted in this topic: papain, for example, digests the antibodies into two Fab fragments and one Fc fragment, whilst pepsin cleaves the antibody below the disulphide bridge, generating an Fc fragment and a divalent F(ab') fragment [15]. The Fab fragment of the antibody contains the specific antigen-binding domain, and the Fc fragment is responsible for the effector properties, such as activation of natural killer cells, activation of the classical pathway of the complement system, and phagocytosis of the antigen [15].
Fig. (1)) Basic structure of antibodies. It consists of a “Y”-shaped molecule composed of two heavy and light chains. Each one of these chains contains multiple constant (C) and one variable (V) region linked by disulphide bonds. The antigen-binding site is located on the N-terminal region, whereas their effector domain resides on the C-terminal region. The red star represents the cleavage by different enzymes, resulting in the Fc fragment and a divalent F(ab') fragment or two Fab fragments and one Fc fragment.Antibodies can operate through several mechanisms to neutralize potential harmful effects by “foreign” organisms. Once an antibody's Fab region binds to the antigen, through complementarity-determining regions (CDRs), its interaction with other ligands is blocked, and an agonist signal is emitted that triggers several signaling cascades [22]. Depending on the Fc region, these “magic bullets” [14] can act through two main mechanisms: (i) antibody-dependent cell-mediated cytotoxicity (ADCC), mediated by natural killer (NK) cells, macrophages, neutrophils, or eosinophils, in which effector cells trigger phagocytosis or lysis of the target cell, whose surface was already covered by specific antibodies [22, 23]; or (ii) complement-dependent cytotoxicity (CDC), where antibodies eliminate the pathogens triggered by the complement cascade on the cell membrane [22, 24].
Five classes of antibodies can be found in mammals, performing different functions (detailed in Table 1) according to each foreign body type that they find: IgA, IgD, IgE, IgG, and IgM [15]. IgG and IgA can be further divided into subclasses, referred to as isotypes, due to polymorphisms in constant regions in the heavy chains. IgG present in humans are of four subclasses – IgG1, IgG2, IgG3, and IgG4 - each presenting its own biological properties, whereas IgA can be split into IgA1 and IgA2 [25]. IgG is the most abundant bloodstream antibody, representing 80% of all the Igs and 20% of the total proteins in human serum (achieving a concentration of 10-25 mg·mL-1) [26, 27]. This class of antibodies has an isoelectric point (pI) comprised between 5.5 and 9.5 [28] and a molecular weight (MW) of approximately 150 kDa [16]. Moreover, IgG is composed of two identical heavy chains (55 kDa each) and two light chains (25 kDa each) [15].
Considering the origin of the antibodies, they can be classified into monoclonal and polyclonal. The differences between them define the limitations of the use of each type of antibody. Most antigens are extremely complex, exhibiting numerous epitopes that are recognized by several lymphocytes [15, 16]. Each lymphocyte is activated in order to proliferate and differentiate into B cells (or plasma cells), and each B cell produces a single mAb – resulting in plasma rich in polyclonal antibodies. Accordingly, human serum is an excellent source of polyclonal antibodies produced from a mixture of lymphocytes capable of recognizing multiple epitopes on the same antigen [15]. Furthermore, polyclonal antibodies are more tolerant to eventual changes that occur in a reduced number of epitopes, such as polymorphisms, glycosylation, or slight denaturation. In addition, when compared to mAbs, polyclonal antibodies have higher stability over a wider range of pH values and salt concentrations [15, 29]. mAbs are highly specific and obtained from a single B lymphocyte cell and recognize not only the same antigen but also the same epitope [15, 29]. Therefore, they are excellent alternatives in specific therapeutic purposes and in the evaluation of changes in molecular conformations, protein-protein interactions, glycosylation/phosphorylation states, and identification of unique members of protein families [15, 29].
mAbs can act through direct or indirect effects. By direct effects, the antibody binds to cell surface receptors, growth factors, membrane-bound proteins, or circulating proteins, modulating the cells [30]. Indirect effects occur when mAbs bind to target cells and stimulate the recruitment of effector cells (natural killer cells and monocytes/macrophages) by promoting cellular cytotoxicity or phagocytosis. Indirect effects can also be achieved through the conjugation of mAbs with toxins, drugs, cytokines, or radioisotopes, providing the specialized delivery of the diagnostic or therapeutic agents [30]. This allows for standardization of tests and, additionally, reduces background noise and cross-reactivity [15, 29]. Given their advantages in different fields and as therapeutic agents in given diseases, mAbs are the focus of the current chapter.
Relevance and Applications of Monoclonal Antibodies
The pharmaceutical industry and medicine have increasingly sought new methods to produce drugs that are more sensitive, specific, and with a lower incidence of risks and adverse effects [7]. In the last twenty years, there have been relevant developments by the introduction of biotherapeutics [8]. Biopharmaceuticals have an active principle that is obtained through the use of microorganisms or genetically modified cells; examples are hormones, recombinantly expressed cytokines, blood factors, replacement enzymes, or antibodies [8]. Advances in molecular biology and in mAbs technology and engineering allowed their introduction into the current important group of biopharmaceuticals [8]. In particular, mAbs differ from traditional drugs since they are produced in biological media while showing unique antigenic specificity to target pathogens [7].
mAbs were first originated by the hybridoma technology developed by Köhler and Milstein [10] in 1975 to produce mAbs with unique target selectivity. This technique starts by injecting a known antigen or mixture of antigens in a mammal (e.g., mouse) to incite an immune response. Then a B cell produces Abs that bind to the injected antigen; posteriorly, these isolated B cells are fused with immortal myeloma cells to produce a hybrid cell line – a hybridoma [30]. Hybrid cells can be grown in culture with a selection medium that only allows the immortalized hybrids to survive. Each hybridoma produces only one specific mAb, which is monitored so that the clone with the desired specificity can be selected and expanded. The products obtained from these individual clones are mAbs specific for a single epitope on an antigen or antigen mixture [38, 39]. Despite the development in mouse-mAbs production, their use as therapeutic agents also presents some drawbacks in humans. In addition to having a short half-life in serum compared to human IgG, they can cause allergic reactions, promote insufficient activation of functions human effectors and, if used continuously in humans, stimulate an immunological reaction - a human antibody response against those of mouse origin, called Human Anti-Mouse Antibodies (HAMAs) response [40].
Aiming at solving the drawbacks associated with mAbs obtained from hybridoma, several efforts have been made over the years to humanize antibodies through genetic engineering. To produce these humanized/fully human mAbs, new techniques have been developed, namely recombinant DNA technology. This technology consists of genetic manipulation, making its amino acid structure very close to the structure of human amino acids while maintaining the specificity of mAbs [41]. Thus, recombinant mAbs (also referred to as second-generation mAbs) are created by the immortality of the immunoglobulin-producing genes rather than being produced by the immortality of the mAb-producing cell. Chimeric antibodies were first generated by the introduction of the mouse sequences for the variable region in a human antibody, allowing to decrease the risk of immunogenicity. However, the need for even less immunogenic antibodies, lead to the development of humanized mAbs through the substitution of the rodent sequences by human sequences, with the exception of the sequences within the antigen-binding complementarity determining regions [30]. Finally, fully human mAbs can be produced by phage display platforms where, in vitro, antibodies are expressed on the surface of a phage used to infect Escherichia coli that replicate and produce the desired mAb, as well as in vivo by producing transgenic mice, expressing human variable domains coupled to hybridoma technology, allowing the production of fully human mAbs with low immunogenic potential [42, 43].
Antibodies development is a field under constant evolution, and new technologies for antibodies discovery are continuously emerging. However, some drawbacks can be associated with the aforementioned phage display platforms, namely, the fact that they usually depend on the random combination and thus unnatural VH and VL antibody pairings [44]. However, it is assumed to be crucial to maintain the original VH and VL pairing in the human B cells [45, 46]. Thus, in recent years, individual B-cell technologies have developed quickly [45]. Single B cell technology is an effective approach, consisting of the direct amplification of the VH and VL region encoding genes from single human B cells and further expression in cell culture technology [45, 46]. This technology attempts to harbor the potential to isolate reactive functional mAbs against conformational determinants that are predominantly present in vivo and difficult to emulate in vitro.
Although highly relevant, the evolution of the described upstream technologies only partially solved one of the downsides of antibodies – immunogenicity. For example, the administration of infliximab (chimeric mAb, brand name – Remicade) in patients with Crohn’s disease makes them develop Human Anti-Chimeric Antibodies (HACAs) that can bind to the therapeutic antibodies, restraining its half-life and clinical effectiveness, as well as infusion-related anaphylaxis in some patients [47]. The development of mAbs from mouse to humanized/fully human partially solved the immunogenicity issues associated with therapeutics. Nonetheless, the development of Human Anti-Human Antibodies (HAHAs) can also be an obstacle, causing the same problems as HACAs [47]. The advantage of fully human mAbs, compared to other classes, is the fact that they allow multiple administrations without causing allergies or immunogenic reactions, being of total safety for chronic or immunosuppressed patients. Hereupon, once the desired hybridoma has been generated, mAbs can be produced through a constant and renewable source, allowing an incessant and reproducible number of antibodies [15].
Monoclonal Antibodies Therapeutics Market
The biopharmaceutical market has been growing steadily since 1982, the year in which the first biopharmaceutical, recombinant human insulin (Humulin) produced by Escherichia coli, was approved for the treatment of diabetes by the Food and Drug Administration (FDA) [48]. Later on, in 1986, a human protein tissue plasminogen activator (tPA) [49] became the first therapeutic protein from mammalian cells to obtain approval in the market [50].
Following these two hallmarks, antibodies have proven to be of high value in the biopharmaceuticals market, both economically and in the improvement of therapeutic efficiency. Their success as therapeutics depends on their efficacy, safety, and pharmacoeconomic issues. Despite the effectiveness and safety of mAbs for human administration, especially when they have a high degree of purity and retain specific activities, access to this type of therapy has been fraught by high manufacturing costs. In clinical practice, therapeutic agents should be selected not only based on their efficacy but also considering their safety and costs. Some drugs have been withdrawn over the years from the market due to safety concerns, whereas the clinical use of other agents is not deemed to be cost-effective [13, 51]. Monoclonal antibodies are the main products in the global biopharmaceutical market, being assessed at approximately US$115.2 billion in 2018 and expected to generate revenues of US$300 billion by 2025 [52]. Their use in human therapy has been increasing in the market, representing 53% of all biopharmaceuticals approved [9].
The use of antibodies for the treatment of several pathologies began in 1890 when Behring and Kitasato [30] found the ability of small doses of diphtheria or tetanus toxin to provide immunity in animals via serum (later explained by the presence of antibodies in the matrix). Though it was only in the early 1960s that the structural features of the antibodies were exposed, and it was only in the next decade that methods for producing mAbs were discovered, as mentioned above [30]. Likewise, in 1986, muromonab-CD3 (Orthoclone OKT3) was the first mAb approved by the FDA and European Medicines Agency (EMA) for the prevention of kidney transplant rejection [30], whereas the first therapeutic mAb (infliximab) for the treatment of inflammatory diseases was approved in 1998 [47]. mAbs can be used either as a monotherapy or in parallel with other standard therapeutic methods, particularly if the disease under treatment is willful to therapy using exclusively conventional techniques. This combination provides an exclusive prospect for the treatment of painful and incurable diseases [13, 51].
There are currently 96 therapeutic mAbs approved by the FDA for the treatment of several diseases (data acquisition in December 2020) and approximately 570 antibody therapeutics at various clinical phases [53]. From the already approved mAbs, approximately 26% correspond to mAbs approved for the treatment of inflammatory diseases [13, 54]. In general, these therapeutic mAbs for inflammatory diseases can act by blocking ligand-receptor interactions targeting the receptor [47, 51, 55, 56] or negatively modulating the cell surface receptor expression that can also be indirectly achieved by ligand targeting [47]. The success of mAbs in inflammatory conditions marks their fast evolution, with over 150 different mAbs currently under clinical trials for further approval by the FDA and EMA [51].
INFLAMMATION OVERVIEW
Inflammation occurs in vascularized connective tissues, involving the capillary beds, plasma, circulating cells, sensory neurons, and cellular and extracellular constituents of this type of tissue. It is a physiological process caused when a chemical, physical, and/or biological invader agent transcends the primary defense barrier of the organism, the epithelial and/or endothelial layer, and its specialized structures [1, 2]. Its role is to restore the homeostasis of the damaged tissue through the activation of the specific components that generate the effector cells and their products (cytokines and antibodies) and non-specific components of immunity, which act through the destruction or isolation of the aggressor agent, involving the action of phagocytic cells and mediators as well as their migration to the lesion site [3, 4]. Inflammation can manifest as an acute or chronic process. During the acute inflammatory process, there are several events mediated by cellular and vascular components that induce morphological and biochemical changes [5]. Among them, three main events are highlighted: i) increased caliber of arterioles, capillaries, and venules, which cause increased blood flow; ii) exudation of plasma proteins, complement factors, and antibodies, which contribute to the development of edema; and iii) migration of leukocytes from the intravascular space to the inflammatory focus [2]. Together, these events characterize the classic signs of inflammation: flushing, heat, tumor, pain, and loss of function [57]. On the other hand, the chronic inflammatory process is long-term and associated with the presence of lymphocytes and macrophages, the proliferation of blood vessels, fibrosis and tissue necrosis [5, 6].
Before an injury, epithelial tissue separates the external environment or a body cavity from the underlying and more delicate connective tissue and body organs. The connective tissue is nurtured by blood vessels and mast cells. Both the inflammatory response and wound healing occur simultaneously but consisting of separate processes that begin immediately after the injury [58]. After the aggression, the inflammatory response is triggered, and the accumulation of cells from the immune system (leukocytes, macrophages, and lymphocytes) occurs, secreting various cytokines and chemokines [58]. Leukocytes express several types of receptors on their surface that recognize external stimuli and release activating signals. Those receptors can be G-protein-coupled receptors (GPCRs) [59], adhesion receptors (selectins and integrins) [60], pattern recognition receptors (PRRs) [61], Fc-receptors [62] and cytokine receptors [63, 64].
G-Protein-Coupled Receptors
GPCRs, known as G protein-linked receptors (GPLR) or serpentine receptors (Fig. 2), are coupled to G proteins. They belong to a large family of protein receptors that distinguish molecules outside the cell and activate internal signal transduction pathways (the cyclic adenosine monophosphate (cAMP) signal and the phosphatidylinositol signal) and finally, cellular responses [59, 65, 66]. They are found in neutrophils and macrophages and participate in host defense and inflammation. These include formyl-peptide receptors [59, 65, 66] that sense bacterial products and tissue injury, receptors for leukotriene B4, platelet-activating factor, and complement fragment [66-69], as well as α-chemokines and β-chemokines receptors [70-72]. All of these strongly activate the chemotactic migration of leukocytes and trigger other responses, such as the production of reactive oxygen species (ROS), exocytosis of intracellular granules and vesicles, are able to augment the responses of leukocytes to subsequent stimulation by other agonists [73]. GPCRs are formed by seven transmembrane domains, with the amino-terminal at the extracellular medium and the carboxyl-terminal in the intracellular medium and interact with G proteins. When an external signaling molecule binds to a GPCR, a conformational change in the GPCR occurs. This change then triggers the interaction between the GPCR and a nearby G protein [59, 65, 66]. The bond promotes a conformational change in the intracellular domain of the receptor, which allows its interaction with a second protein (stimulatory G protein). The occupied receptor causes the replacement of guanosine diphosphate (GDP) bound to the Gα subunit by guanosine triphosphate (GTP), activating the Gα subunit. This subunit dissociates from the Gβγ dimer, and an intracellular signaling cascade is started [59, 65, 66]. It results in the activation of adenylate cyclase, small GTPases, phospholipases, and kinases, eventually capable of controlling the expression of genes that are involved in survival, proliferation, and differentiation [59, 65, 66].
Fig. (2)) Representation of the G-protein-coupled receptors (GPCR) and G protein subunits (GDP: Galpha (α), Gbeta (β), and Ggamma (γ)). The G protein is attached to the inside of the cell membrane but is able to move along it. When GDP is attached to the G protein, it is inactive. The ligand activates the GPCR, inducing a conformational change in the receptor that allows it to function as a guanine nucleotide exchange factor (GEF) that exchanges GDP for GTP – thus turning “on” the GPCR. Created with a paid subscription of BioRender (https://biorender.com).Adhesion Receptors
Adhesion receptors (Fig. 3) are responsible for the initial stabilized binding of leukocytes to the blood vessel wall and their succeeding transendothelial migration to the perivascular tissue, either during normal recirculation and or the inflammation process [60]. Most of them belong to the four protein families: selectins, integrins, cadherins, and the Ig superfamily (IgCAMs). The two major groups involved in the inflammation process are selectins and integrins. The first are single-chain transmembrane glycoproteins that are able to recognize carbohydrate moieties and mediate transient interactions between leukocytes and the vessel wall [60]. Selectins and selectin ligands are mandatory for the rolling phase of the leukocyte adhesion and transmigration cascade [60, 74]. On the other hand, integrins can be defined as heterodimeric transmembrane glycoproteins that are present on all mammalian cells [75]. The most important integrins expressed on leukocytes belong to the β2 integrin [76]. Lymphocyte function-associated antigen 1 (LFA-1) is expressed on all circulating leukocytes, while macrophage-1 antigen (Mac-1) is primarily expressed on myeloid cells such as neutrophils, monocytes, and macrophages. LFA-1 and Mac-1 bind to endothelial intercellular
Adhesion Molecule-1 (ICAM-1) and are involved in different phases of leukocyte adhesion and transendothelial migration [77].
Fig. (3)) Different types of cell adhesion receptors, from left to right: selectin-mediated cell adhesion receptor (sMcAr); integrin-mediated cell adhesion receptor (iMcAr) immunoglobulin superfamily-mediated cell adhesion receptor (IgMcAr), and cadherin-mediated cell adhesion receptor (cMcAr). Part of this Fig. was created with Servier medical art (https://smart.servier.com).Pattern Recognition Receptors
Pattern recognition receptors (PRRs) (Fig. 4) are important in the innate immune response by recognizing the pathogen-associated molecular patterns (PAMPs) and the endogenous molecules released from damaged cells, called damage-associated molecular patterns (DAMPs) [61, 78]. Those pathogens can be bacteria, viruses, parasites, fungi, and protozoa. They are expressed in macrophages, dendritic cells, and in various nonprofessional immune cells (such as epithelial cells, endothelial cells, and fibroblasts) [61, 78]. The PRRs are either localized on the cell surface to perceive extracellular pathogens or within the endosomes. These receptors are involved in triggering pro-inflammatory signaling pathways, stimulating phagocytic responses, or binding to microbes as secreted proteins [61, 78]. They can also be classified into four different classes of PRR families: transmembrane proteins like toll-like receptors (TLRs); C-type lectin receptors (CLRs); cytoplasmic proteins like retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) and nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) [61]. The TLRs function through kinases to stimulate the production of microbicidal substances and cytokines by leukocytes [79]. These proteins have an important relationship with the interleukin- 1 (IL-1) receptor. Several studies [61, 73, 78] have demonstrated that these proteins activate the nuclear factor-κB (NF-kB) and mitogen-activated protein kinase (MAPK) pathway. Furthermore, they regulate the expression of cytokines through various adaptors such as TIR domain-containing adaptor protein (TIRAP), Myeloid differentiation primary response gene 88 (MyD88), TIR-domain-containing adaptor inducing IFNβ (TRIF), Trif-related adaptor molecule (TRAM), and Sterile-α and Armadillo motif-containing protein (SARM). The activation of the NF-kB pathway initiates an adaptive immune response by the production of inflammatory cytokines such as IL-1, IL-6, IL-8, TNF-α, IL-12 [61, 73, 78]. The CLRs, through the recognition of carbohydrates, interact with some microorganisms, for instance, viruses, fungi, and bacteria. CLRs are also involved in the modulation of the innate immune response. These recognitions allow the internalization of the pathogen, subsequent degradation, and then antigen presentation. CLRs can stimulate the production of proinflammatory cytokines or inhibit TLR-mediated immune complexes. Most of these receptors signal through an immunoreceptor tyrosine-based activation motifs (ITAM)-based mechanism, like Fc-receptors or through the activation of protein kinases or phosphatases. CLR-induced signal transduction seems to mainly activate or modulate NF-κB functions [61, 73, 80, 81]. RLRs are a family of RNA helicases that recognize genomic RNA of dsRNA viruses and dsRNA generated as the replication intermediate of ssRNA viruses [61, 73, 78]. After detection of a viral infection, RIG-I and MDA5 cooperate with the adaptor IFN-b-promoter stimulator 1 (IPS-1 also called VISA, CARDIF, and MAVS) via CARD-CARD interactions. IPS-1 activates the release of cytokines and the IKK-related kinase, which activates IRF3/IRF7, resulting in the transcription of type I interferons. IPS-1 also activates NF-κB through recruitment of TRADD, FADD, caspase-8, and caspase-10 [61, 73, 78]. The NLRs are cytoplasmic sensors of PAMPs, DAMPs, and danger signals that lead to transcriptional changes or activate cytokine-processing caspases. They can work together with Toll receptors and regulate the inflammatory and apoptotic response. The protein receptor NOD1 and NOD2 which port CARDs domain, activate NF-κB and MAP-kinase pathways via an adapter (RIP2/RICK). NF-κB then activates the expression of inflammatory cytokines [61, 73].
Fig. (4)) Major pattern recognition receptors (PRRs) presented from left to right: Toll-like receptors (TLRs), C-type lectin receptors (CLRs), cytoplasmic proteins like Retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) and NOD-like receptors (NLRs). Part of this Fig. was created with Servier medical art (https://smart.servier.com).Fc-Receptors
Fc-receptors (Fig. 5) are proteins found on the surface of B lymphocytes, follicular dendritic cells, NK cells, macrophages, neutrophils, eosinophils, basophils, and mast cells [62]. They have the ability to bind to antibodies in their Fc region and are involved in the recognition of Ig-opsonized pathogens, participating as well in immune complex-mediated inflammatory processes [62]. These receptors promote phagocytic or cytotoxic cells to destroy microbes or cells which were infected by antibody-mediated phagocytosis or ADCC. Some viruses (e.g., flaviviruses) use Fc receptors to help them infect cells by a mechanism known as an enhancement of antibody-dependent infection [62]. The most important Fc receptors in neutrophils are the low-affinity Fcγ-receptors [82]. These receptors present important roles in immune complex-mediated activation of neutrophils. The activation of leukocytes by immune complexes requires synergistic ligation of both FcγRIIA and FcγRIIIB [83]. They also express the high-affinity FcγRI molecule [84, 85] and FcαRI, which can mediate IgA-induced inflammatory processes, tumor cell killing [86, 87], and may participate in allergic responses [88, 89] or as pathogenic factors in certain infectious diseases [90]. It is important to remark that signaling usually starts by crosslinking of the Fc receptor. This crosslinking leads to an engagement with other receptors that activate a signaling cascade [91-93].
Fig. (5)) Schematic illustration of an Fc receptor and its interaction with an Ab-coated target. The Fc receptor binds to the antibodies in their Fc region, triggering the recognition of Ig-opsonized pathogens. After contact, a process called phagocytosis occurs, where foreign substances are ingested or engulf in a defensive reaction against infection and invasion of the body. Created with a paid subscription of BioRender (https://biorender.com).Cytokine Receptors
Cytokine receptors (Fig. 6) are cell surface glycoproteins that, when linked to cytokines, transduce a signal. These receptors allow the communication between the cells and the extracellular environment, responding to signals produced in the body [63]. Therefore, the first binding of cytokines to their receptors is a crucial event that is fast, in low concentrations, generally irreversible, and leads to intracellular changes, resulting in a biological response [63]. They comprise six group members, based on their three-dimensional structure, namely type I, type II, Ig superfamily, tumor necrosis factor (TNF) receptor family, chemokine receptor, and transforming growth factor β (TGF- β) receptor family. Conventional cytokine receptors are grouped into type I and type II. Those types of receptors are involved in a few neutrophil functions. Type I receptors consist of transmembrane receptors expressed on the surface of cells, recognizing and responding to cytokines with four α-helical strands [63]. G-CSF and GM-CSF guide the differentiation, survival, and activation of neutrophils [63]. IL-4, IL-6, and IL-15 are involved in the activation of neutrophils and the coordination of the inflammatory response. Type II are similar to type I cytokine receptors, except they do not possess the signature sequence of the common amino acid motif. IFNα/β delays apoptosis of neutrophils [64], whereas IFNγ, which is secreted by NK cells, reacts to antigens and activated T lymphocytes during adaptive immune responses. IFN-γ is a major macrophage activating cytokine [94]. IL-10 presents an inhibitory effect on various functional responses of neutrophils, namely chemokine and cytokine production [95]. Type I and type II cytokine receptors trigger the activation of the JAK-STAT pathway [96-98], Src-family kinases [99-102], the PI3-kinase-Akt pathway [100, 102-104], the ERK and p38 MAPK [105, 106], and the inhibitory SOCS molecules [107-109]. Ig superfamily is involved in the recognition, binding, or adhesion processes of cells. They all possess a domain known as an immunoglobulin domain or fold. Included in this group are molecules involved in the presentation of antigen to lymphocytes, cell adhesion molecules, cell surface antigen receptors, co-receptors, and co-stimulatory molecules of the immune system [63, 110]. TNF receptors are characterized by the ability to bind tumor necrosis factors (TNFs) via an extracellular cysteine-rich domain. They are engaged in apoptosis and inflammation phenomena but also participate in other signal transduction pathways, such as proliferation, survival, and differentiation [110]. The chemokine receptor interacts with a type of cytokine called a chemokine. Each has a rhodopsin-like 7-transmembrane (7TM) structure that allows to couple to G-protein for signal transduction within a cell, making them members of the large protein family of GPCR. After interaction with their specific chemokine ligands, the chemokine receptors trigger a flux in intracellular calcium (Ca2+) ions. This event causes cell responses, including the onset of a process known as chemotaxis that traffics the cell to the desired location within the organism [110]. TGF-β receptors are serine/threonine kinase involved in cell growth, cell differentiation, apoptosis, and cellular homeostasis [63, 64]. TGFβ ligands bind to a type II receptor, which recruits and phosphorylates the type I receptor. Then it phosphorylates the receptor-regulated SMADs (R-SMADs) which bind the coSMAD SMAD. The complex R-SMAD/coSMAD accrues in the nucleus where it joins in the regulation of target gene expression, acting as a transcription factor [63, 64].
Fig. (6)) Types of cytokine receptors: type I and type II families possess extracellular fibronectin-like domains, only differing in the WSXWS motif present in type I, that are not present in type II receptors. The Ig superfamily shares the extracellular region's structural homology with immunoglobulin domains. The TNF receptor family has cysteine-rich motifs in their extracellular regions able to bind ligands. Chemokine receptors are G protein-coupled receptors, and TGF- β receptor family is comprised of Serine/threonine kinase receptors. Part of this Fig. was created with Servier medical art (https://smart.servier.com).After accumulation, mast cells are stimulated by the chemokine alarm chemicals to release histamine, as represented in Fig. (7). Adhesion of neutrophils (first leukocyte to respond) is mediated by adhesion molecules, whose expression is enhanced by secreted proteins known as cytokines [111, 112]. These are secreted by cells in response to microorganisms and other harmful agents, ensuring that neutrophils are recruited into the tissues. The initial interactions of the bearing are mediated by selectins [113, 114], which are divided into three types: one expressed in leukocytes (L-selectin), one in the endothelium (E-selectin), and one in platelets (P-selectin). Its expression is regulated by cytokines produced in response to inflammation and injury. Leukocytes (neutrophils and monocytes) express L-selectin at their surface, and as a result, they roll along the endothelial surface. This rolling is regulated by TNF [115] and IL-1 [116], which induce the endothelial expression of integrin ligands, especially vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM- 1). The expression of integrin ligands induced by the chemoattractants like cytokines and the activation of the integrins in the leukocytes results in a firm adhesion to the endothelium [75]. Due to the chemoattractant gradients in the tissue, leukocytes are able to migrate to the interstitial tissue fluid via chemoattractant receptor-mediated chemotaxis [117]. Through the receptor in the surface of the leukocytes are initiated signals that result in the activation of a second messenger that increases cytosolic Ca2+, activates enzymes, such as protein kinase C and phospholipase A2, and induces polymerization of actin, ensuing in increased quantities in the direction of the cell border and localization of myosin filaments. In the intercellular junctions, there are adhesion molecules called platelet endothelial cell adhesion molecule (PECAM-1) or cluster of differentiation 31 (CD31) that aid in transmigration [111, 118]. The leukocytes migrate in the direction of the locally produced chemoattractant gradient. After crossing the endothelium, the leukocytes leave the circulation and migrate to the tissues towards the lesion site by chemotaxis [119]. When leukocytes reach the site of inflammation, they are activated to perform their functions, recognition of aggressive agents, which release signals and these signals activate the leukocytes to ingest and destroy the hostile agents and amplify the inflammatory reaction [120].
Fig. (7)) Firstly, leukocytes roll and then become activated, adhering to the endothelium. Their penetration occurs in the basement membrane, and they migrate towards the chemoattractants released at the source of the injury. Different molecules have important roles in different phases – selectin in the scroll; chemokines activated neutrophils; integrins in firm adhesion, and CD31 (PECAM-1) in transmigration. Adapted from Kumar et al. [120] and created with a paid subscription of BioRender (https://biorender.com).The functional responses which are the most important for the destruction of microbes and other harmful agents are phagocytosis and intracellular killing. Phagocytosis involves three sequential steps: i) recognition and binding of the particle to be ingested by the leukocyte; ii) its intake, with subsequent formation of the phagocytic vacuole; and iii) death or degradation of the ingested material [121, 122]. Phagocytosis depends on the polymerization of actin filaments and is increased when the microbes are opsonized by specific proteins, opsonin, for which phagocytes express high-affinity receptors [123]. After binding the microorganisms to the receptors, extensions of the cytoplasm flow around them, and the plasma membrane closes in a vesicle called the phagosome. It fuses with the lysosome, resulting in the discharge of the bead content into the phagolysosome [123]. The last step in the removal of infectious agents and necrotic cells is death and degradation within neutrophils and macrophages. The microbial death is carried out by ROS and reactive nitrogen species (RNS) [121, 122]. The generation of ROS is catalyzed by the action of NADPH oxidase, which oxidizes NADPH and reduces oxygen to the superoxide anion (O2•-). O2•- is converted to hydrogen peroxide (H2O2), whichever cannot efficiently destroy microbes. However, H2O2 can be converted to the hydroxyl radical (OH•), or through the enzyme myeloperoxidase (MPO), converted to hypochlorite (OCl•), both potent antimicrobial agents that destroy microbes by halogenation or oxidation of proteins and lipids [124]. NO also participates in microbial death. It reacts with O2•- to generate the peroxynitrite radical (ONOO•). These free radicals attack and damage the lipids, proteins, and nucleic acids of microbes [125]. The elimination of microbes and dead cells activated leukocytes have other roles in defense of the host. After this “cleansing”, macrophages produce growth factors that stimulate endothelial cell proliferation, fibroblasts, and collagen synthesis, that remodel connective tissues, allowing healing and the end of the inflammatory process [126].
Inflammation plays a central role in the fight against pathogens and can set biological reactions to restore the integrity of the organism. Decontrolled amplification of the events may lead to undesirable pathological manifestations such as neoplastic transformations due to the oxidation of DNA, cancer, diabetes, and cardiovascular, neurological, and chronic inflammatory diseases. Therefore, it is necessary to limit the inflammatory process by eliminating the cellular infiltrate and its potentially toxic products [5, 6].
As shown and discussed throughout this section, inflammatory mediators (e.g., cytokines) present complex signaling pathways [127]. Thus, depending on the disease’s scenarios, sometimes it would be more beneficial to target the ligand rather than the receptor, or vice-versa. Several factors contributed to the increased importance of soluble ligands as mAbs targets, such as the growing understanding of their role in the immune system, the easier access to ligands than their receptors, and the easier mapping of epitopes in protein ligands [127]. However, some challenges may appear, such as the possibility of a mAb targeting a ligand but not inhibiting its interaction with the intended receptor, or the challenges associated with targeting GPCRs or other membrane proteins. GPCRs or other membrane proteins are highly challenging for antibodies development since most of the receptor proteins are embedded in the lipid bilayer [128]. Thus, in the specific case of GPCRs, only the N-terminal domain and the extracellular loop regions are accessible as immunogenic epitopes, while the transmembrane components present no inherent therapeutic interest.
It is of utmost importance to understand the biological features of each target in order to assure that the mAb biopharmaceutical is correctly targeted according to the desired treatment. In the next section, an overview of the most relevant/recent mAbs-based therapeutics targeted for the treatment of inflammatory diseases is presented.
MONOCLONAL ANTIBODY-BASED THERAPIES FOR THE TREATMENT OF INFLAMMATION
Interleukin-8 and Interleukin-6
There are more than 40 different chemokines that can be classified according to the location of the cysteine residues at the amino terminus [129]. One of the most widely studied chemokines is interleukin-8 (IL-8), also called chemokine ligand 8 (CXCL8) (Fig. 8) [130]. Based on a chain of biochemical reactions, IL-8 is produced by leukocytes and epithelial and endothelial cells [130]. IL-8 is initially produced as a 99 amino acid precursor peptide and then undergoes cleavage to create various active IL-8 isoforms. The peptide containing 72 amino acids possesses a molecular weight of 8.4 kDa and an isoelectric point > 8.5, which is the mature form secreted by macrophages [38, 131]. IL-8 is a key mediator associated with inflammation, mediating the recruitment and activation of neutrophils through complex signaling mechanisms and extracellular adhesion molecules [38, 132]. Its receptors are found on the surface membrane of various cells of the immune system. The most important are the G protein-coupled receptors, which after binding to IL-8, activate the intracellular signaling cascades and trigger a conformational change, resulting in the activation of G protein [38, 132]. G protein subunits stimulate phosphatidylinositol 4-phosphate kinase (PIPK), which in turn synthesizes phosphatidylinositol 4,5-bisphosphate (PIP2), being the source of inositol trisphosphate (IP3) and phosphatidylinositol (3,4,5)-trisphosphate (PIP3). IP3 leads to the release of Ca2+ that induces chemotaxis, oxidative burst, exocytosis, and eventually the release of more inflammatory mediators [38, 132]. PIP3 activates ras/raf/MAPK pathways, inducing the expression of adhesion molecules, such as integrin, fundamental for chemotaxis [38, 132].
Fig. (8)) 3D structure of interleukin-8 dimer (Image from the Protein Data Bank website (http://rcsb.org/pdb) of PDB ID 1IL8) [133]. N- and C-terminals are also identified.One highly relevant pro-inflammatory cytokine is interleukin-6 (IL-6) (Fig. 9). It was originally discovered in 1986 by Hirano et al. [134] as a T cell-derived B cell stimulatory factor-2, promoting Ig synthesis by activated B-cells. Its production is associated with monocytes, macrophages, lymphocytes, endothelial cells, and fibroblasts and can be stimulated by interleukin-1 (IL-1) and TNF [135, 136]. Human IL-6 consists of a polypeptide cytokine with a four–α-helix structure and is composed of 212 amino acids, including a 28-amino-acid signal peptide, and its gene has been mapped to chromosome 7p21. Even though the core protein possesses 20 kDa, glycosylation is responsible for the size of 21 – 26 kDa of natural IL-6 [135, 136
